Zhao JL, Wang MY, Lv YZ, Zhou YJ. Prognostic value of inflammatory markers in predicting recurrence-free survival in gastrointestinal stromal tumor patients: A nomogram-based approach. World J Gastrointest Oncol 2025; 17(2): 94956 [DOI: 10.4251/wjgo.v17.i2.94956]
Corresponding Author of This Article
Ye-Jiang Zhou, Doctor, MD, PhD, Instructor, Professor, Surgeon, Department of General Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. 1677043397@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jin-Long Zhao, Yan-Zhi Lv, Ye-Jiang Zhou, Department of General Surgery (Gastrointestinal Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Mao-Ying Wang, Department of Anesthesiology, People’s Hospital of Qingbaijiang District, Chengdu 610300, Sichuan Province, China
Author contributions: Zhao JL and Wang MY contributed equally as co-first authors to this study, were primarily responsible for the study design and manuscript writing; Lv YZ was responsible for data interpretation and revision; Zhou YJ participated mainly in the revision and critical review of the manuscript. All authors made a significant contribution to the work reported.
Supported by The Chengdu Municipal Science and Technology Program, No. 2023097.
Institutional review board statement: The researchs are obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts of interest in this work.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ye-Jiang Zhou, Doctor, MD, PhD, Instructor, Professor, Surgeon, Department of General Surgery, The Affiliated Hospital of Southwest Medical University, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. 1677043397@qq.com
Received: March 28, 2024 Revised: October 2, 2024 Accepted: October 25, 2024 Published online: February 15, 2025 Processing time: 295 Days and 17.3 Hours
Abstract
BACKGROUND
There are currently no relevant studies at home or abroad that combine inflammatory indicators and nomograms to predict the prognosis of gastrointestinal stromal tumor (GIST) patients after surgery. The purpose of this study was to investigate the predictive value of related inflammatory indicators [systemic immune-inflammation index (SII), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and monocyte/Lymphocyte ratio (MLR)] in patients undergoing GIST surgery, incorporating relevant risk factors to establish a nomogram prediction model, with the aim of better predicting the prognosis of GIST patients.
AIM
To explore the relationships between the SII, NLR, PLR, and MLR and postoperative recurrence in patients with GIST.
METHODS
This study retrospectively included patients who underwent GIST surgery from January 2014 to January 2017 and analyzed the potential relationships between the preoperative SII, NLR, PLR, and MLR and clinicopathological features. The independent risk factors influencing the prognosis of GIST patients were obtained via multivariate regression analysis, and a nomogram model based on the independent risk factors was established.
RESULTS
Among the 124 GIST patients included in the present study, 31 (25%) experienced recurrence within 5 years. Kaplan-Meier survival analysis revealed a correlation between the MLR and PLR and tumor size (P = 0.016 and P = 0.002, respectively). The preoperative SII, MLR, NLR, and PLR were significantly associated with recurrence-free survival (RFS) (P < 0.05). The multivariate analysis results identified the PLR, MLR, and targeted therapy as independent prognostic factors for patient outcomes.
CONCLUSION
Preoperative MLR and PLR, which are independent risk factors for GIST recurrence, were correlated with RFS. Nomograms based on the PLR, MLR and targeted therapy can be used for clinical treatment.
Core Tip: This study revealed significant correlations between preoperative inflammatory markers [systemic immune-inflammation index, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio (PLR) and monocyte/Lymphocyte ratio (MLR)] and recurrence-free survival in gastrointestinal stromal tumor (GIST) patients. The MLR and PLR were identified as independent risk factors for GIST recurrence. Research has highlighted the prognostic relevance of inflammatory markers in various cancers. Nomograms have been utilized in predicting survival and recurrence in different cancers. This study pioneered the construction of a nomogram based on inflammatory markers for assessing the recurrence risk prognosis in GIST patients. The nomogram demonstrated utility in predicting GIST patient recurrence risk, emphasizing the ongoing sensitivity of inflammatory markers in patients receiving postoperative targeted therapy.
